TAP erectile dysfunction drug
Executive Summary
Preclinical PDE-V inhibitor FR229934 licensed from Fujisawa for all markets, excluding certain Asian countries. TAP withdrew an NDA for its erectile dysfunction drug Uprima (apomorphine) due to safety concerns June 30 (1"The Pink Sheet" July 3, p. 23). TAP plans to study Uprima and FR229934 as a combination therapy